On The Pen: The Weekly Dose 6.4.24

On The Pen GLP-1 News

Send a text

https://ro.co/weight-loss/supply-tracker
https://www.youtube.com/watch?v=mL_krAas70k

Novo Nordisk Advertising:

  • Novo Nordisk launches new advertising campaign "The Power of Wegovy"
  • This advertisement includes the new indication for reduction of cardiovascular risk
  • For 2023, the #5 advertising spend for a drug was Rybelsus at $191 million.  The #6 advertising spend was Ozempic at $187.4 million (increase of 6% from 2022). More than 40% of the 2023 ad spend for Ozempic  went to online video platforms (i.e. social media like youtube)
  • Link: https://www.youtube.com/watch?v=dhretLXYkZ4

Structure Therapeutics GSBR-1290

  • GSBR-1290 is a small molecule GLP-1 pill
  • In a 12-week phase 2 clinical study, a tablet formulation of GSBR-1290 had a weight-loss of 6.9%. This is comparable to Eli Lilly's phase 2 results for olforglipron
  • At Week 12, 67% of GSBR-1290 treated participants achieved ≥6% weight loss and 33% achieved ≥ 10% weight loss, compared to 0% for placebo
  • Also developing next generation combination GLP-1 candidates together with GIP, amylin, glucagon and apelin oral small molecules
  • Link (Madison Muller): https://www.bloomberg.com/news/articles/2024-06-03/structure-reports-early-oral-weight-loss-drug-data-adding-allure


Elon musk tweet:

  • Elon Musk tweeted: Just make a lot of Ozempic/Mounjaro. It’s not inherently expensive. The health benefits of reducing obesity far exceed the downside of GLP-1 inhibitors. We evolved under starving conditions and now make food that is plentiful and delicious. Whether that food is “processed” does matter, but is not a game changer
  • This tweet has currently been seen 325,500 times

Shanghai Stem Cell Type 2 Diabetes Treatment
https://www.scmp.com/news/china/science/article/3263878/chinese-scientists-report-world-first-they-cure-patients-diabetes-cell-therapy

Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

🤝 Visit Our Sponsors!
OTPLinks.com

Decoding GLP-1 Book
Decoding GLP-1: A Guide for Friends and Family of Those On The Pen
Buy Here: https://amzn.to/3Dc66d4

MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT:
Venmo: OnThePen
Ca$h App: ManOnMounjaro

BECOME A MEMBER:
https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join

👉 My Amazon Affiliate Store:
https://www.amazon.com/shop/manonthemounjaroonthepen

WATCH MORE!
📺 We're Live M/W/F at 11 central: onthepen.tv


📲 Contact Me: dave@onthepen.com

Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepen.com.

More description

Send a text

https://ro.co/weight-loss/supply-tracker
https://www.youtube.com/watch?v=mL_krAas70k

Novo Nordisk Advertising:

  • Novo Nordisk launches new advertising campaign "The Power of Wegovy"
  • This advertisement includes the new indication for reduction of cardiovascular risk
  • For 2023, the #5 advertising spend for a drug was Rybelsus at $191 million.  The #6 advertising spend was Ozempic at $187.4 million (increase of 6% from 2022). More than 40% of the 2023 ad spend for Ozempic  went to online video platforms (i.e. social media like youtube)
  • Link: https://www.youtube.com/watch?v=dhretLXYkZ4

Structure Therapeutics GSBR-1290

  • GSBR-1290 is a small molecule GLP-1 pill
  • In a 12-week phase 2 clinical study, a tablet formulation of GSBR-1290 had a weight-loss of 6.9%. This is comparable to Eli Lilly's phase 2 results for olforglipron
  • At Week 12, 67% of GSBR-1290 treated participants achieved ≥6% weight loss and 33% achieved ≥ 10% weight loss, compared to 0% for placebo
  • Also developing next generation combination GLP-1 candidates together with GIP, amylin, glucagon and apelin oral small molecules
  • Link (Madison Muller): https://www.bloomberg.com/news/articles/2024-06-03/structure-reports-early-oral-weight-loss-drug-data-adding-allure


Elon musk tweet:

  • Elon Musk tweeted: Just make a lot of Ozempic/Mounjaro. It’s not inherently expensive. The health benefits of reducing obesity far exceed the downside of GLP-1 inhibitors. We evolved under starving conditions and now make food that is plentiful and delicious. Whether that food is “processed” does matter, but is not a game changer
  • This tweet has currently been seen 325,500 times

Shanghai Stem Cell Type 2 Diabetes Treatment
https://www.scmp.com/news/china/science/article/3263878/chinese-scientists-report-world-first-they-cure-patients-diabetes-cell-therapy

Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

🤝 Visit Our Sponsors!
OTPLinks.com

Decoding GLP-1 Book
Decoding GLP-1: A Guide for Friends and Family of Those On The Pen
Buy Here: https://amzn.to/3Dc66d4

MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT:
Venmo: OnThePen
Ca$h App: ManOnMounjaro

BECOME A MEMBER:
https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join

👉 My Amazon Affiliate Store:
https://www.amazon.com/shop/manonthemounjaroonthepen

WATCH MORE!
📺 We're Live M/W/F at 11 central: onthepen.tv


📲 Contact Me: dave@onthepen.com

Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepen.com.

2024-06-04 17 min
Listen elsewhere

Available Results

Generated results are saved to your library for reuse and search.

No generated results are available for this episode yet.

Transcript

No transcript is available for this episode yet.
Sign in to generate a transcript for review.
Sign in

Chapters

No chapters available.